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Abstract
Background: The primary influenza prevention strategy is focused on annual vaccination according to
the categories identified in the various countries as being at greatest risk of complications. Many studies
were conducted in order to demonstrate that intradermal (ID) vaccine formulation represents a promising
alternative to conventional intramuscular (IM) formulation, especially in subjects with an impaired immune
system. However, there is no consensus whether the efficacy and safety of ID is equivalent to IM in these
subjects. Therefore, we performed a meta-analysis of Randomized Controlled Trials (RCT) to compare the
immunogenicity and safety of ID and IM influenza vaccines in subjects with a depleted immune system.
Methods: We conducted a search strategy of medical literature published until November 2014 in order
to identify RCTs that evaluated the immunogenicity and safety of ID compared with IM influenza vaccines
in immunocompromized patients.
Results: We identified a total of 269 citations through research in electronic databases and scanning reference lists.
Of these, 6 articles were included in the meta-analysis, for a total of 673 subjects. The seroprotection rate induced by
the ID vaccine is comparable to that elicited by the IM vaccine. The overall RR was 1.00 (95 % CI = 0.91 -1.10) for A/
H1N1 strain, 1.00 (95 % CI = 0.90-1.12) for A/H3N2 and 0.99 (95 % CI = 0.84 -1.16) for B strain. No significant differences
in the occurrence of systemic reactions were detected (17.7 % in the ID group vs 18.2 % in the IM group) with a
pooled RR = 1.00 (95 % CI = 0.67 -1.51), whereas ID administration caused significantly more injection site reactions
with a mean frequency of 46 % in the ID group compared to 22 % in the IM group, with a pooled RR = 1.89 (95 %
CI = 1.40 -2.57).
Conclusions: The ID influenza vaccine has shown a similar immunogenicity and safety to the IM influenza
vaccine in immunocompromized patients, and it may be a valid option to increase compliance to influenza
vaccination in these populations.
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Background
The primary influenza prevention strategy is focused on
annual vaccination according to the categories identified
as being at greatest risk of complications. Recently, in the
United States, the recommendations for influenza vaccin-
ation has been extended to a larger population by the
Advisory Committee on Immunization Practices (ACIP)
[1, 2], and all subjects aged ≥ 6 months were included.
The common route of influenza vaccine administration
is intramuscular (IM) but, more recently, an intradermal
(ID) vaccine formulation, licensed in the European Union
in February 2009 and by the Food and Drug Administra-
tion (FDA) in May 2011, has become available.
Among the several strategies investigated to increase
the immunogenicity of influenza vaccine, researchers
have focused attention on ID formulation that appears a
valid alternative to IM route because this mode of deliv-
ery may be advantageous in terms of immunogenicity,
dose sparing, greater acceptability among the patients
and lower risk of accidental puncture for healthcare
workers, because needle-free injection devices can evoke
less pain and stress in patients and avoid unsafe injection
practices, in line with the World Health Organization
(WHO) objectives [3, 4].
Many studies have been conducted in order to demon-
strate that the ID influenza vaccine represents a promis-
ing alternative to the IM formulation, especially in
subjects with a limited vaccination response caused by
an impairment of the immune defenses as a result of
many different mechanisms, such as treatment with
immunosuppressive drugs or HIV infection [5–7]. How-
ever, there is no consensus whether the immunogenicity
and safety of the ID vaccine is equivalent to the IM
formulation in these subjects. Therefore, we performed a
meta-analysis of Randomized Controlled Trials (RCT) to
compare the immunogenicity and safety of ID and IM
influenza vaccine in immunocompromized subjects.
Methods
Search strategy for identification of studies
We conducted a search strategy of medical literature
published until November 2014 in order to identify
RCTs that evaluated the immunogenicity and safety of
ID influenza vaccines compared with IM influenza
vaccines in immunocompromized patients. The U.S.
National Library of Medicine (MEDLINE), Embase,
Cochrane Central Register of Controlled Trials,
Scopus and Monthly Influenza Bibliography of the
National Institute for Medical Research electronic
database were searched. Also, we reviewed the refer-
ence lists from all retrieved publications and the most
recent review articles, in order to identify additional
undetected published studies.
The following Medical Subject Heading (MeSH) terms
were used individually and in combination in the search:
“autoimmune disease”, “cancer”, “comparison”, “HIV infec-
tion”, “immunodeficiency disorder”, “immunosuppressive
therapy”, “influenza vaccine”, “intradermal administration”,
“meta-analysis”, “randomized controlled trials”, “transplant
recipients”.
Inclusion criteria
Articles that met the following criteria were included: (a)
RCTs; (b) primary studies; (c) enrollment of all kinds of
immunocompromized patients; (d) comparing the im-
munogenicity and/or safety of the ID vaccine with the
standard IM vaccine measuring one or more of the fol-
lowing outcomes: seroprotection and/or seroconversion
rate to assess immunogenicity, local reactions and/or
general symptoms as safety indicators, according to
European Medicines Agency (EMA) criteria; (e) published
through November 2014. Trials that compared ID influ-
enza vaccine with IM administration in healthy popula-
tion, studies that used pandemic vaccine, re-analyses,
reviews, letters and abstracts were excluded.
Assessment of study quality
Two of the authors independently reviewed the studies
included in the meta-analysis to appraise the quality of
the individual trials using criteria developed by Chalmers
et al. [8] and the method of Jadad et al. [9]. Studies were
classified as high quality if their score was higher than
the median calculated for each quality scale.
Data extraction
The following data were collected from each study:
(a) name of first author, year of publication, and geo-
graphic setting; (b) study design; (c) description of
intervention in the ID and IM group; (e) number of
subjects in each group; f ) patient characteristics (age,
gender and cause of impairment of the immune sys-
tem); g) outcome data: 1) percentage of subjects with
a post-vaccination titer ≥40 for each strain, referred
as the seroprotection rate; 2) percentage of subjects
with either a pre-vaccination titer <10 and a post-
vaccination titer ≥40, or a fourfold rise in titer from a
pre-vaccination titer ≥10, defined as the seroconver-
sion rate; 3) percentage of subjects with at least one
injection site reaction (pain, erythema, swelling, prur-
itus, induration and ecchymosis); 4) percentage of
subjects with at least one systemic sign or symptom
(fever, myalgia, headache, malaise and shivering).
Statistical analysis
Risk Ratio (RR) of seroprotection was calculated as the
ratio of the percentage of subjects in which seroprotec-
tion occurred in those who received ID formulation
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compared with those who received traditional IM
formulation. Similarly, the RR of seroconversion was
calculated as the ratio of the percentage of subjects in
which seroconversion occurred in ID and IM group.
Safety was assessed as the ratio of the percentage of par-
ticipants that had at least one local and/or general
adverse event associated with the ID vaccine compared
with those who received the IM vaccine. All meta-analyses
were carried out using the DerSimonian and Laird
random-effect model [10]. The Mantel-Haenszel method
(fixed effects model) [11] was also used. Statistical hetero-
geneity was assessed using Cochran Q and I2 measure; an
I2 value above 25 % may be considered low heterogeneity,
a value above 50 % and 75 % were predefined as moderate
and high heterogeneity [12].
Sensitivity analyses
To explore the reasons for heterogeneity, we performed
separate sensitivity analyses by pooling studies that in-
volved subjects with similar characteristics (i.e. having a
similar disease that causes immunodeficiency), details of
intervention as antigen content, type of ID devices used,
and number of injection sites. Also, we performed a meta-
analysis to assess the potential effect of the studies’ quality
on the results, by combining only studies with Jadad
scores greater than or equal to the median (high quality).
Finally, publication bias was explored by searching
eventual unpublished RCTs in two clinical trial regis-
tries: ClinicalTrials.gov and EudraCT.
All statistical analyses were performed using Stata soft-
ware program, version 11 (Stata Corporation. College
Station, TX).
The reporting of study’s findings was in accordance
with the PRISMA statement [13]. PRISMA checklist
was used to ensure inclusion of relevant information
(See Additional file 1).
Results
Study characteristics
We identified a total of 269 citations through research in
electronic database and scanning references lists. Of
these, 6 articles [14–19] met all inclusion criteria and
were available for the meta-analysis. A flow diagram de-
scribes the reasons for excluding the studies from the
meta-analysis (Fig. 1). In particular, only two studies
performed in immunocompromized patients were ex-
cluded: the first because it was a letter [20] and the
second because it verified the role of a booster dose
of ID injection in patients vaccinated with a standard
dose of IM injection [21].
The main characteristics and extracted data of the
included RCTs are summarized in Table 1. The studies
were carried out from 2009 until 2013. Patients were 18-
77 years old, with a mean age of 48 to 54 in the ID
group and 48 to 55 years in the IM group. Males
accounted for 50 % to 73 % of participants in the ID
group and 47 % to 68 % in the IM group. In 3 studies
participants were transplant recipients [16, 17, 19],
whilst one other involved patients with solid tumors
[15], and another comprised of HIV-infected patients
[18] and the remaining study was conducted in patients
with different diseases causing immunosuppression [14].
ID trivalent inactivated split-virion vaccine was used in 5
studies [15–19] and in the remaining one a subunit vac-
cine was used [14]; the antigen content ranged from 3 to
15 μg hemagglutinin (HA)/strain. In the IM group, the
traditional vaccination with the same amount of antigen
(15 μg HA) of the trivalent inactivated split-virion vac-
cine was used in all trials. In 2 studies, ID vaccine was
administered at two separate injection sites [17, 19].
Two studies used Mantoux technique [14, 15], while in
the others the devices employed were microneedles [18]
and microinjection systems [16, 17, 19].
Only one trial did not report local and systemic re-
actions [19], in one study they were pooled [14], in
the remaining studies each local and systemic adverse
reaction was reported for IM and ID group [15–18].
In 3 studies also subjects with at least one local [16–18]
or systemic [15–17] reaction were reported and these
values were extracted for the meta-analysis, in others
the most frequent local [15] or systemic [18] reaction
was extracted. Local reactions ranged from 19 % to
80.6 % in the ID group and from 5.5 % to 48.4 % in the
IM group, with an overall frequency of 46 % in the ID
group and of 22 % in the IM group. In the ID group the
most frequent local reactions were erythema and swell-
ing followed by pruritus, whereas pain was reported
only in two studies [15, 16] and the frequency was simi-
lar in the ID and IM group. Systemic adverse events
ranged from 1.9 % to 54.8 % in the ID group and from
3.6 % to 51.6 % in the IM group (overall frequency
17.7 % ID group vs 18.2 % IM group). The most fre-
quent systemic reported symptoms were shivering and
headache.
Data quality
The mean quality scores of the individual studies
using the Chalmers et al. [8] scale ranged from 0.32
to 0.75 (mean = 0.57; median = 0.61). With regard to
the Jadad et al. [9] criteria, the mean score was 2.8
(median 3), all trials were classified as open-label and
reported a description of withdrawals or dropouts
after randomization. According to the Jadad score
only one study [15] was below the median, whereas
according to the Chalmers score three studies were
below the median [14–16]. Scores of individual stud-
ies are reported in Table 1.
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Meta-analysis
The results of the meta-analyses that compared the im-
munogenicity of the ID influenza vaccine with the IM
vaccine involving 673 patients for the meta-analysis on
seroprotection and 517 patients for that on seroconver-
sion are shown in Table 2.
The seroprotection rate induced by the ID vaccine was
comparable to that elicited by the IM vaccine. The overall
RR was 1.00 (95 % CI = 0.91-1.10) for A/H1N1 strain, 1.00
(95 % CI = 0.90-1.12) for A/H3N2 and 0.99 (95 % CI =
0.84-1.16) for B strain. The I2 statistic test showed a low-
moderate heterogeneity (Fig. 2). Similarly, the seroconver-
sion rate achieved with the ID vaccine was found to be
equivalent to that of the IM vaccine for each strain (A/
H1N1: RR = 1.00, 95 % CI = 0.84-1.19; A/H3N2: RR = 1.08,
95 % CI = 0.86-1.36; B: RR = 0.92, 95 % CI = 0.72-1.17) and
no heterogeneity was found.
The meta-analyses on vaccine safety (Fig. 3), con-
ducted on 4 trials to estimate injection site and sys-
temic reactions, showed no significant differences in
the occurrence of systemic side effects, with a pooled
RR = 1.00 (95 % CI = 0.67-1.51). ID administration
caused significantly more injection site reactions (RR =
1.89, 95 % CI = 1.40-2.57). The I2 statistic test showed no
heterogeneity across the trials both for systemic and for
local side effects.
Sensitivity analysis
Pooled analyses after restriction to quality of the
studies (high quality, low quality), to antigen content
(≤9 μg, ≥12 μg), to type of ID devices used (Mantoux
technique, micro injection system), to number of injection
sites (one injection, two injections) and to the cause of im-
munosuppression (transplantation, other diseases) showed
that the investigated factors did not substantially influence
the findings for all strains (Table 2).
In the sensitivity analyses on seroprotection, hetero-
geneity disappeared when analyses were stratified by
antigen content (≤9 μg) for the A/H3N2 and B strains,
by other causes of immunosuppression excluding
Fig. 1 Flow chart of the published trials evaluated for inclusion in the meta-analysis
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Table 1 Characteristics of included RCTs on intradermal versus intramuscular administration of influenza vaccine
Authors Country Interventions Units of
treatment
ID/IM







A/H1N1 A/H3N2 B A/H1N1 A/H3N2 B
ID IM N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
ID/IM ID/IM ID/IM ID/IM ID/IM ID/IM ID/IM ID/IM
L Gelinck et al.
2009 [14]
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Y Jo et al. 2009
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ID: Intradermal; IM: Intramuscular; TIV: trivalent inactivated vaccine; HA: hemagglutinin; SPL: split vaccine; SU: subunit vaccine
aPain at injection site, erythema, swelling, pruritus, induration and ecchymosis
bFever, myalgia, headache, malaise and shivering
cFrequency of local and systemic adverse reactions calculated on 125 participants that recorded whether or not they had suffered adverse reactions
dReferred to swelling that was the most frequent symptom suffered both in ID and IM groups
eReferred to fever or myalgia
fCanada and Switzerland
gReferred to shivering that was the most frequent symptom suffered both in ID and IM groups
hTwo doses of ID vaccine were delivered for a cumulative dose of 12 μg antigen per strain


































All studies 6 673 1.00 (0.91-1.1) 0.272;21.5 6 673 1.00 (0.9-1.12) 0.042;56.6 6 673 0.99 (0.84-1.16) 0.072;50.5
High qualityb 5 566 1.01 (0.86-1.18) 0.177; 36.7 5 566 1.02 (0.88-1.19) 0.05;57.9 5 566 0.98 (0.79-1.22) 0.041;59.8
Low qualityb 1 107 1.02 (0.94-1.11) - 1 107 0.98 (0.92-1.05) - 1 107 0.94 (0.79-1.16) -
Antigen content ≥12 μg 3 358 1.13 (0.9-1.43) 0.248;28.4 3 358 1.03 (0.77-1.39) 0.01;78.4 3 358 0.94 (0.61-1.47) 0.01;78.1
Antigen content≤ 9 μg 3 315 0.95 (0.8-1.14) 0.067;63 3 315 0.99 (0.93-1.05) 0.368;0.1 3 315 0.96 (0.84-1.09) 0.935;0
One injection 4 377 0.99 (0.86-1.15) 0.136;45.9 4 377 1.04 (0.9-1.2) 0.087;54. 3 4 377 0.98 (0.87-1.11) 0.783;0
Two injections 2 296 1.05 (0.84-1.3) 0.291;10.2 2 296 0.96 (0.72-1.29) 0.015;83.1 2 296 0.8 (0.34-1.99) 0.003;88.8
Mantoux technique 2 263 0.93 (0.71-1.24) 0.012;84 2 263 1.00 (0.89-1.13) 0.177;45.2 2 263 0.95 (0.82-1.1) 0.819;0
Micro injection system 4 410 1.06 (0.92-1.22) 0.378;2.9 4 410 1.02 (0.83-1.26) 0.027;67.4 4 410 0.98 (0.73-1.32) 0.027;67.4
Cause of immunosuppression:
Transplantation 4 344 1.11 (0.86-1.43) 0.228;30.7 4 344 1.04 (0.8-1.35) 0.22;68.9 4 344 0.91 (0.61-1.36) 0.018;70.2
Other diseasesb 3 488 0.98 (0.87-1.1) 0.216;34.7 3 488 0.99 (0.93-1.05) 0.465;0 4 488 0.97 (0.86-1.1) 0.98;0
SEROCONVERSION
All studies 5 517 1.00 (0.84-1.19) 0.532;0 5 517 1.08 (0.86-1.36) 0.569;0 5 517 0.92 (0.72-1.17) 0.578;0
High qualityb 4 410 1.04 (0.79-1.36) 0.399; 0 4 410 1.00 (0.75-1.34) 0.52;0 4 410 1.13 (0.77-1.66) 0.823;0
Low qualityb 1 107 0.98 (0.78-1.23) - 1 107 1.23 (0.83-1.83) - 1 107 0.80 (0.59-1.09) -
Antigen content ≥12 μg 3 358 1.17 (0.85-1.62) 0.545;0 3 358 1.06 (0.73-1.55) 0.36;2 3 358 1.11 (0.7-1.75) 0.641;0
Antigen content≤ 9 μg 2 159 0.95 (0.77-1.16) 0.443;0 2 159 1.1 (0.81-1.45) 0.35;0 2 159 0.85 (0.64-1.13) 0.33;0
One injection 3 221 0.99 (0.74-1.34) 0.242;29.6 3 221 1.16 (0.86-1.57) 0.341;7 3 221 0.86 (0.65-1.13) 0.589;0
Two injections 2 296 1.09 (0.77-1.55) 0.961;0 2 296 0.94 (0.63-1.4) 0.735;0 2 296 1.14 (0.68-1.9) 0.359;0
Mantoux technique 1 107 0.98 (0.78-1.23) - 1 107 1.23 (0.83-1.83) - 1 107 0.80 (0.59-1.09) -
Micro injection system 4 410 1.04 (0.79-1.36) 0.399; 0 4 410 1.00 (0.75-1.34) 0.52;0 4 410 1.13 (0.77-1.66) 0.823;0
Cause of immunosuppression:
Transplantation 3 358 1.17 (0.85-1.62) 0.545;0 3 358 1.06 (0.73-1.55) 0.36;2 3 358 1.11 (0.7-1.75) 0.641;0
Other diseasesc 2 159 0.95 (0.77-1.16) 0.443;0 2 159 1.1 (0.81-1.45) 0.35;0 2 159 0.85 (0.64-1.13) 0.33;0
aRRs and 95 % CIs were calculated with the DerSimonian and Laird random effect model
bReferred to Jadad scores












transplantation for the same strains, and by injection site
and by micro injection system for B strain. Results of
meta-analysis on seroconversion did not substantially
change in all the stratified analyses (Table 2).
All presented data were derived from random effects
models; the results of meta-analyses performed using
fixed effects models substantially did not change (data
not shown).
Publication bias
To explore publication bias we searched for similar studies
registered in ClinicalTrials.gov and EudraCT databases to
Fig. 2 Forest plots of the risk ratio of seroprotection for intradermal compared with intramuscular administration of influenza vaccine according to strains
Fig. 3 Forest plots of the risk ratio of vaccine safety for intradermal compared with intramuscular administration of influenza vaccine. Systemic
side effects: at least one systemic sign or symptom (fever, myalgia, headache, malaise and shivering). Local side effects: at least one injection site
reaction (pain, erythema, swelling, pruritus, induration and ecchymosis)
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verify the number and eventually the results of similar
unpublished studies. We found all of the studies in-
cluded in our meta-analysis, whereas three studies on
the same topic were not published. Of these, one was
not completed (the reasons for which were not speci-
fied) and 2 were completed in 2010 and in 2012 but
were not published.
Discussion
The present meta-analysis is the first comparing the im-
munogenicity and safety of a seasonal ID influenza vac-
cine with the traditional IM formulation in subjects with
an impaired immune system.
The major findings provide support to an equivalence
of ID formulation immunogenicity in respect to IM in-
fluenza vaccine measured through both seroconversion
and seroprotection and consistently demonstrated for
the three vaccine strains. The equivalence was reached
although antigen content was lower in the ID formula-
tion in most included studies, thus providing advantages
in terms of dose sparing.
The findings of this meta-analysis are consistent with
those of the meta-analysis by Marra et al. [22] that
focused more on the immunogenicity of ID influenza
vaccination versus IM formulation in subjects who were
≥18 years of age, but excluded immunocompromized
subjects. These Authors, in a meta-analysis that included
13 trials, found no difference in the overall immunogen-
icity outcomes and, interestingly, they found a significant
association between increasing doses of the ID formula-
tion with increasing immunogenicity response, and
when the ID antigen content was analogous to that of
the IM formulation (15 μg), the ID vaccine appeared to
be superior to the IM formulation for all the strains.
This is in line with our results demonstrating an equiva-
lence in studies with lower doses of antigen content in
the ID formulation.
The efficacy of influenza vaccination has been exten-
sively evaluated in healthy adults and in the elderly, and
recently an umbrella meta-analysis has critically reviewed
and re-analysed 15 meta-analyses performed in healthy
children, in healthy adults, and in the elderly, and those
evaluating the pre-pandemic vaccines (H5N1) and the
pandemic 2009 (H1N1) vaccines [23]. Although the
results are reported in terms of clinical efficacy and
therefore not directly comparable to ours, most seasonal
influenza vaccines showed both efficacy and effectiveness
at an acceptable or high level for laboratory-confirmed
cases and of modest magnitude for clinically-confirmed
cases.
A number of reviews [24–26], and two meta-analysis
[27, 28] have specifically evaluated the role of several
vaccinations, including influenza, in immunocompro-
mized patients, since, compared to healthy adults, the
immunogenicity of vaccines may be reduced, and the
balance between potential benefits and harms of influ-
enza vaccines is hard to establish. In particular, the
meta-analyses showed a significant effect in the preven-
tion of influenza-like illness and laboratory confirmed
influenza in immunocompromized patients vaccinated
with the IM formulation compared to placebo or unvac-
cinated controls, and no difference in the odds of
influenza-like illness compared to vaccinated immuno-
competent controls. Less striking results were found for
seroconversion and seroprotection rates, and the Au-
thors conclude recommending influenza vaccination in
immunocompromized patients. Moreover, in all of
these reviews, one of the unresolved issues is the role
played by new strategies to improve vaccine response,
such as ID administration. Therefore, our results meet
the need to clarify the usefulness of ID administration
in terms of immunogenicity in patients with weak-
ened immune systems.
Our meta-analysis has highlighted that the ID influ-
enza vaccine in these patients was well tolerated without
causing excess harm; indeed, the two modes of adminis-
tration had an overlapping systemic reactogenity and the
ID formulation had a higher amount of local adverse
reactions than the IM formulation. However, the higher
frequency of injection site reactions in the ID formula-
tion is mostly related to erythema, swelling and pruritus,
and these adverse events are not generally a cause of
concern for patients [29], while the frequency of pain,
the most troublesome symptom, is low and comparable
to that caused by IM administration [15, 30]. Thus,
based on the results of our meta-analysis, adverse events
do not seem to represent a significant safety issue and
an obstacle to the acceptability of the ID vaccine. In-
deed, previous studies have shown that the acceptability
of the ID vaccine is similar [29, 31, 32] or even greater
[33] than that of the IM formulation mainly due to the
specific injection device. In particular, Foy et al. [33]
found that immediately after receiving the ID influenza
vaccine, the overall satisfaction rate was 99.6 % versus
88.2 % after the IM vaccine.
Subjects with weakened immune systems are at “high
risk” of adverse outcomes as a result of infection with
seasonal influenza, as indicated by the WHO [34].
Therefore, any potential initiatives that may enhance the
individual willingness to get vaccinated against influenza
should be promoted. In this perspective, the advantages
provided by the ID influenza vaccine appear useful and
successful [32] and support policies oriented to recom-
mendation of influenza vaccination to immunocompro-
mized patients. In this context efforts are strongly needed
to improve general practitioners commitment to adher-
ence to vaccination policies, considering their crucial role
in the primary health needs of vulnerable patients [35, 36].
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Limitations of the study
The present meta-analysis also has inherent potential
limitations. Few studies have examined the immunogen-
icity of the two influenza vaccines on immunocompro-
mized patients; therefore achieving sufficient statistical
power might be difficult, and a cautious approach in the
interpretation of results is warranted, especially for
stratified analysis, where comparisons were frequently
based on three or four trials.
Moreover, the results might have been affected by
publication bias, because only published trials have been
included and positive studies are more likely than nega-
tive ones to be published. Since the low number of stud-
ies included in the meta-analysis did not allow any
investigation of publication bias through funnel plots or
formal tests [37, 38], we tried to explore registries of
RCTs to verify the extent of unpublished studies. We
retrieved 9 RCTs on the topic of interest and, of these,
three were unpublished. Although delayed publication of
RCTs on vaccines has been reported [39], the potential
for publication bias exists.
Another possible limitation is the heterogeneity among
studies, which included subjects with various degrees of
immuno-suppression due to different diseases, and to
other factors that might have adversely influenced im-
mune responses (eg. age, co-morbidity). Indeed, the het-
erogeneity was no more significant when analyses were
stratified by type of disease. Moreover, studies used dif-
ferent antigen content in the ID vaccine arm, thus redu-
cing the ability of the meta-analysis to identify a
recommended dose.
Further research is required to confirm the results of
this meta-analysis, to determine the cost-effectiveness of
the ID influenza vaccine and to evaluate whether ID
administration in the real world, during seasonal vaccin-
ation campaign, will be able to increase the adherence to
vaccination due to its greater acceptability.
Conclusions
The ID influenza vaccine has shown a similar im-
munogenicity and safety to the IM administration in
immunocompromized patients, and it may be a valid
option to increase compliance to influenza vaccination
in these populations.
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